Blood safety strategies for human T-cell lymphotropic virus in Europe.
about
Leucoreduction of blood components: an effective way to increase blood safety?Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic ReviewA multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven samplingEpidemiological Aspects and World Distribution of HTLV-1 Infection.Human T lymphotropic virus types 1 and 2: a point of viewInfection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety.Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.Inflammatory manifestations of HTLV-1 and their therapeutic options.Human T-lymphotropic virus antibody screening of blood donors: rates of false-positive results and evaluation of a potential donor reentry algorithm.Human T-lymphotropic virus and transfusion safety: does one size fit all?Evaluation of human T-lymphotropic virus prevalence/co-infection rates for a four-year period in a non-metropolitan blood center in Southeast Brazil.No significant HTLV seroprevalence in German people who inject drugs.Reconsideration of blood donation testing strategy for human T-cell lymphotropic virus in Australia.Delayed seroconversion and rapid onset of lymphoproliferative disease after transmission of human T-cell lymphotropic virus type 1 from a multiorgan donor.The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors.The outcome of donor screening for human T-cell lymphotropic virus infection in The Netherlands.[Human retrovirus HTLV-1: descriptive and molecular epidemiology, origin, evolution, diagnosis and associated diseases].Viral Oncology: Molecular Biology and Pathogenesis.Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy.
P2860
Q26771857-FCD43839-BF6A-4671-8EC9-843676EEE905Q28066384-E281BAFF-60D3-4F33-B15B-9ECDD22876BFQ34584310-AED91F7E-5E7F-410F-B544-49940174696FQ36400825-402FC54A-6796-4145-95BD-55C31DB26384Q37212598-E0377395-A49A-4C6C-9A16-AC05317FB1DAQ37296863-EBF1EE51-54C9-43D0-941F-7EE02660863DQ37520190-229F0AFB-D907-4889-8FF6-BEE3D44BB52BQ38262169-3A6451DC-A449-4F03-9A4A-FA5E1172AF5CQ38414305-CA0AE1F7-088B-4973-A5D7-3F8873A237BCQ38590004-C8346E90-AF69-4292-8746-F1A5DC190EA9Q39756418-EAA75BB7-A0DE-4641-ACF3-F8804F859900Q40075316-22A209C1-6616-483E-A28B-353B9E57B90AQ41928215-6DC0FC52-247D-4828-B8B1-8C303D4DE079Q42275863-5ADDF70F-0D29-4DAB-A11F-68489D7F9519Q42283514-AD39FEC1-4466-4DFE-9F3C-8B191BFE9731Q45363593-F3AB0EC4-8CD7-4E94-B68E-84CDC3990814Q46373938-CD1C5D1D-B3A8-41DB-9165-FE6656DFA5D8Q47571734-73C97C49-15E1-4F11-8D0B-A7A4779D0911Q55239037-1610E21D-7CC8-4CBA-A838-255FB56DDA52
P2860
Blood safety strategies for human T-cell lymphotropic virus in Europe.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Blood safety strategies for human T-cell lymphotropic virus in Europe.
@en
Blood safety strategies for human T-cell lymphotropic virus in Europe.
@nl
type
label
Blood safety strategies for human T-cell lymphotropic virus in Europe.
@en
Blood safety strategies for human T-cell lymphotropic virus in Europe.
@nl
prefLabel
Blood safety strategies for human T-cell lymphotropic virus in Europe.
@en
Blood safety strategies for human T-cell lymphotropic virus in Europe.
@nl
P2093
P2860
P1433
P1476
Blood safety strategies for human T-cell lymphotropic virus in Europe.
@en
P2093
European Network of Transfusion Medecine Societies
J Pillonel
S Laperche
Steering Committee
P2860
P304
P356
10.1111/J.1423-0410.2008.01136.X
P577
2009-02-01T00:00:00Z